STRA13 interacts with STAT3 and modulates transcription of STAT3-dependent targets

Journal of Molecular Biology

Volumn 340, Issue 4, 2004, Pages 641-653

  Ivanova, A V ^a   Ivanov, S V ^a   Zhang, X ^b   Ivanov, V N ^c   Timofeeva, O A ^b   Lerman, M I ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; APRF, acute phase response factor; Fas; IL 6, interleukin 6; PV, sodium pervanadate; STAT3; STATs, signal transducers and activators of transcription; STRA13; TAD, transactivation domain; transcriptional regulation

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR STAT3ALPHA; TRANSCRIPTION FACTOR STAT3BETA; TRANSCRIPTION FACTOR STRA13; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL STRAIN 3T3; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TWO HYBRID SYSTEM; YEAST;

EID: 3042653466     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.05.025     Document Type: Article

References (59)

1. Ivan M., Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:2001;27-34
2. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
3. Gnarra J.R., Zhou S., Merrill M.J., Wagner J.R., Krumm A., Papavassiliou E., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci.USA. 93:1996;10589-10594
4. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr, Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA. 93:1996;10595-10599
5. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24:1999;68-72
6. Ivanov S.V., Kuzmin I., Wei M.H., Pack S., Geil L., Johnson B.E., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl Acad. Sci. USA. 95:1998;12596-12601
7. Ivanov S.V., Liao S.Y., Ivanova A.V., Danilkovitch-Miagkova A., Tarasova N., Weirich G., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158:2001;905-919
8. Ivanova A.V., Ivanov S.V., Danilkovitch-Miagkova A., Lerman M.I. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J. Biol. Chem. 276:2001;15306-15315
9. Boudjelal M., Taneja R., Matsubara S., Bouillet P., Dolle P., Chambon P. Overexpression of Stra13, a novel retinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of P19 cells. Genes Dev. 11:1997;2052-2065
10. Sun H., Taneja R. Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms. Proc. Natl Acad. Sci. USA. 97:2000;4058-4063
11. Dhar M., Taneja R. Cross-regulatory interaction between Stra13 and USF results in functional antagonism. Oncogene. 20:2001;4750-4756
12. Shen M., Kawamoto T., Yan W., Nakamasu K., Tamagami M., Koyano Y., et al. Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem. Biophys. Res. Commun. 236:1997;294-298
13. Shen M., Kawamoto T., Teramoto M., Makihira S., Fujimoto K., Yan W., et al. Induction of basic helix-loop-helix protein DEC1 (BHLHB2)/Stra13/Sharp2 in response to the cyclic adenosine monophosphate pathway. Eur. J. Cell. Biol. 80:2001;329-334
14. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J. Inhibition of PPARgamma2 gene expression by the HIF-1-regulated gene DEC1/Stra13. A mechanism for regulation of adipogenesis by hypoxia. Dev. Cell. 2:2002;331-341
15. Sun H., Lu B., Li R.Q., Flavell R.A., Taneja R. Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nature Immunol. 2:2001;1040-1047
16. Seimiya M., Bahar R., Wang Y., Kawamura K., Tada Y., Okada S., et al. Clast5/Stra13 is a negative regulator of B lymphocyte activation. Biochem. Biophys. Res. Commun. 292:2002;121-127
17. Meyer T., Begitt A., Lodige I., van Rossum M., Vinkemeier U. Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J. 21:2002;344-354
18. Wegenka U.M., Buschmann J., Lutticken C., Heinrich P.C., Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol. Cell. Biol. 13:1993;276-288
19. Hirano T., Ishihara K., Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:2000;2548-2556
20. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene. 19:2000;2474-2488
21. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 19:2000;6613-6626
22. Schaefer T.S., Sanders L.K., Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc. Natl Acad. Sci. USA. 92:1995;9097-9101
23. Caldenhoven E., van Dijk T.B., Solari R., Armstrong J., Raaijmakers J.A., Lammers J.W., et al. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271:1996;13221-13227
24. Chakraborty A., White S.M., Schaefer T.S., Ball E.D., Dyer K.F., Tweardy D.J. Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood. 88:1996;2442-2449
25. Shao H., Quintero A.J., Tweardy D.J. Identification and characterization of cis elements in the STAT3 gene regulating STAT3 alpha and STAT3 beta messenger RNA splicing. Blood. 98:2001;3853-3856
26. Schaefer T.S., Sanders L.K., Park O.K., Nathans D. Functional differences between Stat3alpha and Stat3beta. Mol. Cell. Biol. 17:1997;5307-5316
27. Sasse J., Hemmann U., Schwartz C., Schniertshauer U., Heesel B., Landgraf C., et al. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol. Cell. Biol. 17:1997;4677-4686
28. Ni Z., Lou W., Leman E.S., Gao A.C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60:2000;1225-1228
29. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59:1999;5059-5063
30. Burke W.M., Jin X., Lin H.J., Huang M., Liu R., Reynolds R.K., Lin J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 20:2001;7925-7934
31. Xia Z., Sait S.N., Baer M.R., Barcos M., Donohue K.A., Lawrence D., et al. Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk. Res. 25:2001;473-482
32. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 99:2002;252-257
33. Gordon J.A. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201:1991;477-482
34. Reed J.C., Nowell P.C., Hoover R.G. Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation. Proc. Natl Acad. Sci. USA. 82:1985;4221-4224
35. Matikainen S., Sareneva T., Ronni T., Lehtonen A., Koskinen P.J., Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 93:1999;1980-1991
36. Grigorieva I., Grigoriev V.G., Rowney M.K., Hoover R.G. Regulation of c-myc transcription by interleukin-2 (IL-2). J. Biol. Chem. 275:2000;7343-7350
37. Zhu M., John S., Berg M., Leonard W. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell. 96:1999;121-130
38. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol. Cell. 7:2001;517-528
39. Rossner M.J., Dorr J., Gass P., Schwab M.H., Nave K.A. SHARPs: mammalian enhancer-of-split- and hairy-related proteins coupled to neuronal stimulation. Mol. Cell. Neurosci. 9:1997;460-475
40. Garriga-Canut M., Roopra A., Buckley N.J. The basic helix-loop-helix protein, sharp-1, represses transcription by a histone deacetylase-dependent and histone deacetylase-independent mechanism. J. Biol. Chem. 276:2001;14821-14828
41. Fujimoto K., Shen M., Noshiro M., Matsubara K., Shingu S., Honda K., et al. Molecular cloning and characterization of DEC2, a new member of basic helix-loop-helix proteins. Biochem. Biophys. Res. Commun. 280:2001;164-171
42. Gingras S., Simard J., Groner B., Pfitzner E. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucl. Acids Res. 27:1999;2722-2729
43. Paulson M., Pisharody S., Pan L., Guadagno S., Mui A.L., Levy D.E. Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J. Biol. Chem. 274:1999;25343-25349
44. Zhang J.J., Zhao Y., Chait B.T., Lathem W.W., Ritzi M., Knippers R., Darnell J.E. Jr. Ser727-dependent recruitment of MCM5 by Stat1alpha in IFN-gamma-induced transcriptional activation. EMBO J. 17:1998;6963-6971
45. Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., Coqueret O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J. Biol. Chem. 277:2002;8004-8011
46. Nakajima H., Brindle P.K., Handa M., Ihle J.N. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J. 20:2001;6836-6844
47. Darnell J.E. Jr. STATs and gene regulation. Science. 277:1997;1630-1635
48. Lew D.J., Decker T., Strehlow I., Darnell J.E. Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol. Cell. Biol. 11:1991;182-191
49. Ellenberger T., Fass D., Arnaud M., Harrison S.C. Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev. 8:1994;970-980
50. Kiuchi N., Nakajima K., Ichiba M., Fukada T., Narimatsu M., Mizuno K., et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Expt. Med. 189:1999;63-734
51. Bromberg J.F. Activation of STAT proteins and growth control. Bioessays. 23:2001;161-169. Review
52. Dinarello C.A., Novick D., Puren A.J., Fantuzzi G., Shapiro L., Muhl H., et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J. Leukoc. Biol. 63:1998;658-664
53. Miscia S., Marchisio M., Grilli A., Di Valerio V., Centurione L., Sabatino G., et al. Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells. Cell Growth Differ. 13:2002;13-18
54. Bromberg J.F., Horvath C.M., Besser D., Lathem W.W., Darnell J.E. Jr. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18:1998;2553-2558
55. Fukada T., Hibi M., Yamanaka Y., Takahashi-Tezuka M., Fujitani Y., Yamaguchi T., et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 5:1996;449-460
56. Chen R.H., Chang M.C., Su Y.H., Tsai Y.T., Kuo M.L. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 2:1999;3013-23019
57. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317
58. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976
59. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Jr. Stat3 as an oncogene. Cell. 98:1999;295-303